中华中医药学刊

调营益卫方联合XELOX方案治疗晚期大肠癌临床研究

PDF下载

肖永娟 , 童艳 , 吴喆 , 鲁志兵

中华中医药学刊 | 省级项目平台 2026,44(6): 248-251

收起

中华中医药学刊 |省级项目平台 2026 , 44 (6) : 248 -251

调营益卫方联合XELOX方案治疗晚期大肠癌临床研究

全屏

[Author(id=1319631274864653294, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319631274931762160, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631274864653294, language=EN, stringName=Yongjuan XIAO, firstName=Yongjuan, middleName=null, lastName=XIAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319631275019842545, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631274864653294, language=CN, stringName=肖永娟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=萍乡市人民医院，江西萍乡 337000, bio={"content":"

肖永娟（1983-），女，江西萍乡人，副主任中医师，硕士，研究方向：中医内科。

"}, bioImg=null, bioContent=

肖永娟（1983-），女，江西萍乡人，副主任中医师，硕士，研究方向：中医内科。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319631274780767210, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, xref=null, ext=[AuthorCompanyExt(id=1319631274789155819, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China), AuthorCompanyExt(id=1319631274797544428, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=萍乡市人民医院，江西萍乡 337000)])]), Author(id=1319631275078562803, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319631275162448885, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631275078562803, language=EN, stringName=Yan TONG, firstName=Yan, middleName=null, lastName=TONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319631275229557750, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631275078562803, language=CN, stringName=童艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=萍乡市人民医院，江西萍乡 337000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319631274780767210, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, xref=null, ext=[AuthorCompanyExt(id=1319631274789155819, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China), AuthorCompanyExt(id=1319631274797544428, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=萍乡市人民医院，江西萍乡 337000)])]), Author(id=1319631275313443832, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319631275393135610, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631275313443832, language=EN, stringName=Zhe WU, firstName=Zhe, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319631275472827387, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631275313443832, language=CN, stringName=吴喆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=萍乡市人民医院，江西萍乡 337000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319631274780767210, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, xref=null, ext=[AuthorCompanyExt(id=1319631274789155819, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China), AuthorCompanyExt(id=1319631274797544428, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=萍乡市人民医院，江西萍乡 337000)])]), Author(id=1319631275539936253, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1319631275623822335, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631275539936253, language=EN, stringName=Zhibing LU, firstName=Zhibing, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1319631275690931200, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, authorId=1319631275539936253, language=CN, stringName=鲁志兵, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=萍乡市人民医院，江西萍乡 337000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1319631274780767210, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, xref=null, ext=[AuthorCompanyExt(id=1319631274789155819, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China), AuthorCompanyExt(id=1319631274797544428, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1317115171189936478, companyId=1319631274780767210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=萍乡市人民医院，江西萍乡 337000)])])]

肖永娟, 童艳, 吴喆, 鲁志兵

作者信息

萍乡市人民医院，江西萍乡 337000

作者简介:

肖永娟（1983-），女，江西萍乡人，副主任中医师，硕士，研究方向：中医内科。

Clinical Study of Tiaoying Yiwei Prescription (调营益卫方) Combined with XELOX in Treatment of Advanced Colorectal Cancer

Yongjuan XIAO, Yan TONG, Zhe WU, Zhibing LU

Affiliations

Pingxiang People's Hospital, Pingxiang 337000, Jiangxi, China

出版时间: 2026-06-10 doi: 10.13193/j.issn.1673-7717.2026.06.048

文章导航

摘要

收起

目的

观察调营益卫方联合XELOX方案治疗晚期大肠癌的临床效果。

方法

研究纳入晚期大肠癌患者合计60例（2022年10月—2023年12月收治），将患者以随机数字表法分为观察组与对照组，各组30例，对照组患者进行XELOX方案治疗，观察组患者采取XELOX方案+调营益卫方治疗，各组数据观察：治疗效果、治疗前后中医证候积分（神疲乏力、大便干结或稀溏、腹痛、面色萎黄、形体消瘦）变化与血清癌胚抗原（carcinoembryonic antigen，CEA）、糖类抗原199（carbohydrate antigen199，CA199）与糖类抗原242（carbohydrate antigen，CA242）指标变化、T细胞亚群（T lymphocyte subsets）指标变化与自然杀伤细胞（natural killer cell，NK）指标变化、不良反应、肠癌生存质量评分（Functional Assessment of Cancer Therapy：Colorectal Cancer，FACT-C4.0中文版）以及体力状况KPS评分变化。

结果

对照组患者与观察组患者治疗总有效率比较（46.67%vs73.33%），P<0.05；治疗前，各组患者中医证候积分（神疲乏力、大便干结或稀溏、腹痛、面色萎黄、形体消瘦）、CEA、CA199、CA242、CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺、NK指标、KPS评分及肠癌生存质量评分等指标比较（P>0.05），治疗后各组患者中医证候积分（神疲乏力、大便干结或稀溏、腹痛、面色萎黄、形体消瘦）、CEA、CA199、CA242均下降，KPS评分及肠癌生存质量评分提升，观察组患者治疗后中医证候积分（神疲乏力、大便干结或稀溏、腹痛、面色萎黄、形体消瘦）、CEA、CA199、CA242指标低于对照组，KPS评分及肠癌生存质量评分均高于对照组（P<0.05）；对照组患者治疗后CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺、NK指标均下降，观察组患者治疗后CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺、NK指标均上升，两组治疗后CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺、NK指标比较（P<0.05）；观察组患者恶心呕吐、食欲不振、脱发、腹泻等化疗不良反应发生率低于对照组（P<0.05）。

结论

调营益卫方联合XELOX方案治疗晚期大肠癌疗效显著，患者临床病症、免疫功能、生活质量均改善，还可降低患者部分不良反应，安全性较高，值得应用。

关键词

晚期大肠癌 / 调营益卫方 / XELOX方案 / 疗效 / 免疫功能 / 中医证候积分

Abstract

收起

Objective

To observe the clinical effect of Tiaoying Yiwei Prescription (调营益卫方) combined with XELOX in the treatment of advanced colorectal cancer.

Methods

A total of 60 patients with advanced colorectal cancer admitted from October 2022 to December 2023 were included in this study. The patients were divided into observation group and control group by random number table method, with 30 patients in each group. The patients in the control group were treated with XELOX regimen, while those in the observation group were treated with XELOX regimen+Tiaoying Yiwei Prescription. Before and after treatment, the treatment effect, the TCM symptom scores (fatigue, dry or loose stools, abdominal pain, sallow complexion, and emaciation), the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA199), carbohydrate antigen (CA242), T lymphocyte subsets and natural killer (NK) cell changes, adverse reactions, bowel cancer survival quality score (Functional Assessment of Cancer Therapy: Colorectal Cancer, FACT-C4.0 Chinese version) and physical condition Karnofsky Performance Status (KPS) score changes of two groups were compared.

Results

The total effective rate between the control group and the observation group was significant (46.67% vs 73.33%) (P<0.05). Before treatment, the scores of TCM symptoms (fatigue, dry or loose stools, abdominal pain, sallow complexion, and emaciation), the levels of CEA, CA199, CA242, CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺, NK indicators, KPS scores, and survival quality scores in each group were not significant (P>0.05). After treatment, the scores of TCM symptoms (fatigue, dry or loose stools, abdominal pain, sallow complexion, and emaciation), the levels of CEA, CA199 and CA242 decreased in each group, while the KPS scores and survival quality scores improved. The scores of TCM symptoms (fatigue, dry or loose stools, abdominal pain, sallow complexion and emaciation), the levels of CEA, CA199 and CA242 in the observation group were lower than those in the control group after treatment, while the KPS scores and survival quality scores were higher than those in the control group (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK indicators in the control group decreased, while those in the observation group increased. The comparison of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK indicators between the two groups after treatment showed significance (P<0.05). The incidence of chemotherapy-related adverse reactions such as nausea and vomiting, loss of appetite, hair loss and diarrhea was lower in the observation group than that in the control group (P<0.05).

Conclusion

Tiaoying Yiwei Prescription combined with XELOX regimen has significant efficacy in the treatment of advanced colorectal cancer, which can improve the clinical symptoms, immune function and quality of life of thr patients, and also reduce some side effects of patients. It is safe and worthy of application.

Key words

advanced colorectal cancer / Tiaoying Yiwei Prescription (调营益卫方) / XELOX regimen / curative effect / immune function / TCM symptoms scores

引用本文

肖永娟, 童艳, 吴喆, 鲁志兵. 调营益卫方联合XELOX方案治疗晚期大肠癌临床研究. 中华中医药学刊, 2026 , 44 (6) : 248 -251 . DOI: 10.13193/j.issn.1673-7717.2026.06.048

Yongjuan XIAO, Yan TONG, Zhe WU, Zhibing LU. Clinical Study of Tiaoying Yiwei Prescription (调营益卫方) Combined with XELOX in Treatment of Advanced Colorectal Cancer[J]. Chinese Archives of Traditional Chinese Medicine, 2026 , 44 (6) : 248 -251 . DOI: 10.13193/j.issn.1673-7717.2026.06.048

基金

收起

江西省中医药管理局科技计划项目(2022B443)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

［1］

张学娟，吴冬寒，王玮莉，等．子午流注穴位按摩联合神阙灸对癌因性疲乏的晚期大肠癌患者T淋巴细胞亚群和生活质量的影响［J］．长春中医药大学学报，2021，37（5）：1122-1125.

［2］

胡玥，王瑞平，邹玺，等．“扶土疏木解毒汤”对晚期大肠癌患者化疗及靶向治疗后免疫功能和生存质量的影响研究——附30例临床资料［J］．江苏中医药，2022，54（4）：47-50.

［3］

杨华南，鱼麦侠，许鹏．龙慈仙胶囊联合CapeOx方案治疗大肠癌临床观察［J］．现代中西医结合杂志，2022，31（6）：780-783，809.

［4］

韩朵朵，王新苗，李杰．基于“承宣布化”理论论治大肠癌［J］．吉林中医药，2022，42（5）：516-519.

［5］

申丽丽，王晞星，郝淑兰，等．国医大师王晞星三期论治大肠癌肝转移的中西医结合思路［J］．湖南中医药大学学报，2022，42（8）：1233-1237.

［6］

侯敏艳，朱超林．朱超林中医治疗晚期肠癌经验［J］．吉林中医药，2020，40（2）：181-184.

［7］

刘佳琴，蒋盛昶，曹如柔，等．基于回顾性分析探讨中药治疗大肠癌的用药规律［J］．中医药导报，2020，26（16）：108-111.

［8］

赵轩竹，何国平，梅汉玮，等．中医药联合化疗治疗大肠癌的临床进展［J］．现代中西医结合杂志，2022，31（14）：2036-2039.

［9］

李星星，叶威，周丽．基于中医传承辅助平台挖掘郭勇治疗大肠癌用药及组方规律［J］．浙江中西医结合杂志，2022，32（5）：465-469.

［10］

史孟华，张相安，张双喜，等．中医药治疗大肠癌相关信号通路的研究进展［J］．中国实验方剂学杂志，2022，28（8）：272-282.

［11］

中华人民共和国卫生部医政司．中国常见恶性肿瘤诊治规范：第9分册［M］．北京：北京医科大学中国协和医科大学联合出版社，2002：10-11.

［12］

刘刚．健脾燥湿汤联合穴位按压对老年大肠癌术后化疗患者的临床疗效［J］．中成药，2022，44（7）：2421-2424.

［13］

肖铃，商健．中西医结合治疗大肠癌的研究进展［J］．癌症进展，2022，20（2）：127-129.

［14］

程艳野，习弯弯，毛雪杨，等．基于网络药理学-分子对接技术研究贞芪扶正颗粒治疗大肠癌相关性疲乏的作用机制［J］．癌变·畸变·突变，2022，34（5）：335-343.

［15］

尹凤婷，周小航，闫广利，等．基于肠道菌群探讨中药改善大肠癌的研究进展［J］．广东药科大学学报，2022，38（2）：138-145.

［16］

陈劲壮，何燕彬，黄彬，等．基于网络药理学和分子对接探讨八宝丹协同奥沙利铂治疗大肠癌的作用机制［J］．康复学报，2022，32（3）：213-223.

［17］

邹孟龙，黄晓燕，陈雅璐，等．基于国家专利数据库分析中药复方治疗大肠癌用药规律［J］．国际中医中药杂志，2022，44（6）：680-684.

［18］

王立雅，郑红刚．朴炳奎“和其不和”思想在大肠癌治疗中的运用［J］．吉林中医药，2022，42（6）：647-651.

［19］

陈映文，廖泳欣，林敏，等．华蟾素注射液联合5-氟尿嘧啶对大肠癌LoVo细胞黏附侵袭能力的影响［J］．中国医药导刊，2022，24（2）：140-143.

［20］

罗星，陈琪．健脾消癌方联合化疗对大肠癌患者肿瘤标志物及预后的影响［J］．陕西中医，2022，43（9）：1249-1251.

［21］

祝利民，史海霞，徐振晔．徐振晔教授中医药辨证论治大肠癌的临床数据挖掘［J］．世界科学技术-中医药现代化，2021，23（6）：1773-1783.

［22］

陈欣，张海山，王立雅，等．从中医药证关系论全国名中医朴炳奎治疗大肠癌中药性味归经特点［J］．中医药学报，2021，49（6）：68-71.

［23］

赵彪，杜欣颖．中医在大肠癌整合治疗中的应用［J］．医学争鸣，2021，12（1）：18-23.

［24］

綦向军，陈新荣，莫嘉浩，等．基于数据挖掘的中医药治疗大肠癌组方规律分析［J］．中国中药杂志，2021，46（15）：4016-4022.

［25］

刘静，朱琰，范佳伟．及早中医药健脾治疗对大肠癌术后患者生存质量影响［J］．辽宁中医药大学学报，2021，23（9）：6-9.

［26］

王燕莹，王雷，殷晓玲，等．增益方联合化疗治疗大肠癌术后脾虚型患者临床研究［J］．山东中医杂志，2021，40（5）：476-481.

［27］

王贺平，许博文，李杰．基于数据挖掘探讨李杰辨治大肠癌的临床研究［J］．中国中医基础医学杂志，2021，27（4）：623-630.

［28］

王飞，徐湘江，王振强，等．参苓胃消胶囊联合XELOX方案治疗大肠癌的临床研究［J］．现代中西医结合杂志，2021，30（18）：1958-1962.

［29］

薛明杰，孙妍，黄敏．四君子汤治疗大肠癌患者化疗不良反应及对血清PLT、AST、ALT水平变化的影响［J］．现代肿瘤医学，2021，29（7）：1161-1165.

［30］

王静，刘少玉，齐文颖，等．杜怀棠教授“调气通腑”法治疗大肠癌经验［J］．环球中医药，2021，14（1）：106-108.

［31］

王馨，方志军，徐荷芬，等．基于“同气相求”理论的大肠癌临证应用探讨［J］．海南医学院学报，2021，27（9）：709-712.

［32］

孙敏，徐可，万光升，等．中西医治疗调节大肠癌肠道菌群研究进展［J］．中华中医药杂志，2021，36（2）：951-954.

2026年第44卷第6期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13193/j.issn.1673-7717.2026.06.048

首发时间：2026-10-14
出版时间：2026-06-10

补充材料

相关文章

文章信息

作者

出版历史

基金

江西省中医药管理局科技计划项目(2022B443)

作者信息

萍乡市人民医院，江西萍乡 337000

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2026.06.048

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT